Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


                                  PHARMASSET, INC.
            CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                                     (UNAUDITED)

                           Three Months Ended           Six Months Ended
                               March 31,                   March 31,
                               ---------                   ---------
                           2009          2008          2009          2008
                           ----          ----          ----          ----

    REVENUES            $1,902,679      $464,292    $2,366,970      $928,583
                        ----------      --------    ----------      --------

    COSTS AND EXPENSES:
      Research and
       development      13,694,247     8,990,469    27,717,177    19,540,840
      General and
       administrative    2,893,504     3,809,073     6,962,874     6,428,818
                         ---------     
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to a new market ... global orthobiologics market was valued at USD 3,754.6 million in ... 5,519.9million in 2019at a CAGR of 5.9% from 2013 to ... and above is afflicted by bone and joint disorders, and ... 2020. This has and will continue to increase the demand ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Only Collagen-Based Filler Proven To Last Through One Year , ... Ortho Dermatologics today announced that the U.S. Food and Drug ... safety data through 12 months for EVOLENCE(R), a collagen-based dermal ... and folds, such as nasolabial folds. , , To ...
... RAMAT GAN, Israel, June 8 EarlySense announced ... cleared for,marketing by the U.S. Food and Drug Administration ... Dutch notified body, in accordance with the,EC-Directive 93/42/EEC. Both ... home, hospital or clinical setting. In November 2007, EarlySense,announced ...
... under the Pacific Ocean, could provide a powerful clean-up ... issue of the journal, Microbiology , Professor Gejiao ... Wuhan, PR China describe how a particular strain of ... effective in removing manganese from solutions, converting it into ...
Cached Biology Technology:Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4EarlySense's EverOn(TM) System Receives FDA Clearance and CE Mark Certification 2
(Date:8/29/2014)... German . ... cycle on Earth and in biological wastewater treatment plants. ... on nitrite as their source of energy. An international ... at the University of Vienna, has now shown that ... of energy. The oxidation of hydrogen with oxygen enables ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Ready for mating at the right time 2Ready for mating at the right time 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... that some brain tumours in larvae of the fruit fly ... cells to grow. The removal of some of these genes ... are crucial for tumour development. The study, headed by ICREA ... Science . One of the characteristics of ...
... mankind,s migration from Africa to the New World, and the ... international study that for the first time will dig deep ... a mile) down under 300 meters (about a fifth of ... researchers will look back in time to collect a massive ...
... University of Exeter have developed a new approach to ... up the process of finding vaccines. Dr Andrea ... the university,s Cornwall Campus, has pioneered a simple screen ... gene structures of pathogenic* bacteria. The screen allows ...
Cached Biology News:Some brain tumors mimic the genetic program of germline cells 2Back to the dead (sea, that is) 2Finding new ways to tackle environmental diseases 2
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
Biology Products: